Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update.

Abstract

Clinical management of persistent adrenocorticotropin hormone (ACTH) excess in Nelson syndrome (NS) and Cushing disease (CD) remains a challenge. Somatostatin and its analogs as octreotide decrease ACTH secretion through somatostatin receptors of pituitary cells. To our knowledge, there are no reports on the effect of long-acting repeatable octreotide (oct-lar) on hormonal secretion and quality of life in patients with NS and CD who failed conventional therapy. Herein, we describe the effects of treatment with oct-lar (20 mg/month intramurally) in 1 woman with NS and 2 women with persistent CD. Oct-lar therapy reduced ACTH secretion and improved the quality of life in NS patient. By contrast, in CD patients, it failed to control ACTH and cortisol secretion, and the quality of life remained unchanged.

• Authors: Alejandro L Arregger, Estela M L Cardoso, Olga B Sandoval, Elida G Monardes Tumilasci, Rocío Sanchez, Liliana N Contreras
• Journal: American journal of therapeutics (Am J Ther) 2014 Jul-Aug Vol. 21 Issue 4 Pg. e110-6 ISSN: 1536-3686 [Electronic] United States
• PMID: 22820717 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Delayed-Action Preparations
• Adrenocorticotropic Hormone
• Octreotide
• Hydrocortisone

Topics

• Adrenocorticotropic Hormone (metabolism)
• Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
• Delayed-Action Preparations
• Female
• Humans
• Hydrocortisone (metabolism)
• Middle Aged
• Nelson Syndrome (drug therapy, physiopathology)
• Octreotide (administration & dosage, therapeutic use)
• Pituitary ACTH Hypersecretion (drug therapy, physiopathology)
• Quality of Life
• Treatment Outcome